Department of Community and Family Health, College of Public Health, University of South Florida, 13201 Bruce B. Downs Blvd, MDC 56, Tampa, FL 33612, USA.
Sex Transm Dis. 2010 Oct;37(10):644-52.
Human papillomavirus (HPV), the most common sexually transmitted virus in the United States, remains a considerable public health problem. HPV has been associated with anogenital warts and cancers in males and females, affecting the cervix, penis, anus, vulvar, and vaginal regions; and more recently, has been associated with oropharyngeal cancers. In 2006, the Food and Drug Administration (FDA) approved a prophylactic quadrivalent HPV vaccine for females (9-26 years); in 2009, this approval extended to males of this same age group. However, limited research has examined attitudes and other factors related to males' intention to receive the vaccine.
Factors associated with HPV vaccination intentions/willingness were examined among: (1) males (N=296) participating in a HPV natural history study with repeated exposure to HPV information; and (2) male University students (N=198) "unexposed" to intense HPV messages and testing.
About 94% of HPV study participants and 62% of University males reported intentions/willingness toward vaccination, respectively. In multivariate analyses, among HPV study males, concerns about getting an appointment (odds ratio [OR], 0.06; confidence interval [CI], 0.01- 0.68), getting time off (OR, 0.14; CI, 0.03- 0.63), and "other" barriers (OR, 0.04; CI, 0.01- 0.17) were negatively associated with vaccine intentions. Among University males, vaccine awareness (OR, 0.06; CI, 0.02- 0.17), low risk perceptions (OR, 0.11; CI, 0.04-0.33), and unimportance of provider recommendations (OR, 9.66; CI, 2.69 -34.68) were negatively associated with willingness to vaccinate.
Repeated exposure to HPV information and provider recommendations may be critical for male vaccine promotion. Future research is needed to increase understanding of factors that may prevent men from receiving HPV vaccination.
人乳头瘤病毒（HPV）是美国最常见的性传播病毒，仍然是一个相当严重的公共卫生问题。HPV 与男性和女性的生殖器疣和癌症有关，影响宫颈、阴茎、肛门、外阴和阴道区域；最近，还与口咽癌有关。2006 年，食品和药物管理局（FDA）批准了一种用于女性（9-26 岁）的预防性四价 HPV 疫苗；2009 年，这一批准扩展到了同一年龄组的男性。然而，有限的研究调查了与男性接种疫苗意愿相关的态度和其他因素。
在重复接触 HPV 信息的 HPV 自然史研究中，对（1）男性参与者（N=296）和（2）未接触 HPV 大量信息和检测的男性大学生（N=198）的 HPV 疫苗接种意愿进行了与 HPV 疫苗接种意愿/意愿相关的因素的调查。
约 94%的 HPV 研究参与者和 62%的大学生男性报告了接种疫苗的意愿。在多变量分析中，在 HPV 研究男性中，预约的担忧（比值比 [OR]，0.06；置信区间 [CI]，0.01-0.68）、请假（OR，0.14；CI，0.03-0.63）和“其他”障碍（OR，0.04；CI，0.01-0.17）与疫苗接种意愿呈负相关。在大学生男性中，疫苗意识（OR，0.06；CI，0.02-0.17）、低风险认知（OR，0.11；CI，0.04-0.33）和对提供者建议的不重要性（OR，9.66；CI，2.69-34.68）与接种疫苗的意愿呈负相关。
反复接触 HPV 信息和提供者的建议对于男性疫苗推广可能至关重要。需要进一步研究，以增加对可能阻止男性接种 HPV 疫苗的因素的理解。
